Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04018092
Other study ID # IRB201901780 -N
Secondary ID R01AG064587F31AG
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 12, 2020
Est. completion date April 2025

Study information

Verified date May 2024
Source University of Florida
Contact Dawn Bowers, Ph.D.
Phone 352-273-6152
Email dawnbowers@phhp.ufl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this multi-site double blinded randomized sham-controlled Phase II clinical trial is to test a novel, relatively low cost, low risk, and potentially high impact therapeutic intervention in older adults who are at increased risk for Alzheimer's disease. The intervention involves transcranial and intranasal delivery of near infrared (NIR) light via light emitting diodes, aka photobiomodulation. The overall hypothesis, based on animal and pilot studies, is that exposure to NIR stimulation will have beneficial effects on brain health via influence on mitochondrial function as measured by changes in 31P MRS-based markers of ATP, neural network changes in functional connectivity (rs-fMRI), and improved cognitive performance. To test this hypothesis, 168 older adults with subjective cognitive complaints, and a first-degree family history of Alzheimer's disease will be randomized to sham or real treatment groups. Neuromiaging and ocgnitive outcome measures will be obtained, before and after a 12-week intervention involving transcranial and intranasal NIR-PBM. The intervention protocol will involve "lab" and "home" sessions, and a 3 month post-intervention follow-up. This trial will determine: 1) whether NIR stimulation, relative to sham, improves performance on memory and executive tasks sensitive to hippocampal and frontal brain function in older adults with increased risk for Alzheimer's disease; 2) whether NIR stimulation, relative to sham, enhances brain function and connectivity measured by changes in MRS phosphorous ATP and resting state functional connectivity; and 3) how differences in demographic, neuroimaging, and Alzheimer-related risk factors influence the brain response to NIR stimulation versus sham in older adults with increased risk for Alzheimer's disease. Results will provide key insights into whether this novel NIR intervention can enhance cognition in older adults with increased risk for Alzheimer's disease and will provide the necessary data for a future Phase III randomized clinical trial.


Description:

This multi-site randomized sham controlled trial proposes to test a novel, non-invasive, low risk and low cost brain stimulation approach for enhancing cognition and brain health in cognitively normal older adults who are at increased risk for Alzheimer's disease. The intervention involves transcranial and intranasal delivery of near-infrared light (NIR; 808-904 nm) via light emitting diodes placed on the scalp or intranasally using a dosing that resulted in positive effects in our pilot studies. We plan to test the hypothesis that targeted NIR stimulation will have positive effects on brain health via influence on mitochondrial function as measured by changes in Magnetic Resonance Spectroscopy (MRS)-based markers of ATP, neural network changes as indexed by changes in functional connectivity based on resting state-fMRI, and improved cognitive performance. We plan to randomize 168 older adults, ages 65-89 years, to Active or Sham intervention conditions. To be included, participants must have subjective cognitive complaints, based on an index of Subjective Cognitive Impairment (SCI), and a family history of Alzheimer's disease in a first degree relative. Performance on standardized neuropsychological measures must be unimpaired psychometricallyl. The intervention itself will last for 12 weeks and include lab sessions (16 total) and daily at home sessions. In the lab, both transcranial and intranasal delivery of NIR light will be delivered using Medx and Vielight stimulation technologies, whereas the daily at home sessions will involve intranasal stimulation only. The sham and active conditions are identical in all respects except that sham devices will not deliver NIR stimulation. The primary outcome is an episodic memory measure involving spatial navigation that is linked to hippocampal function, sensitive to MCI and Alzheimer's disease, and an analogue to the Morris Water maze. Secondary outcomes include executive function task and neuroimaging indicators of ATP function (31-P MRS) and connectivity changes based on rs-fMRI. Exploratory outcomes include 'traditional' neuropsychological measures that are used clinically, along with measures and indices (e.g., APOE-4 status)that might potentially mediate or moderate study outcome. Assessments will occur at baseline (Month 1), after 12 weeks of intervention (Month 4), and 3 month post intervention (Month 7). Imaging outcomes will be assessed only at baseline and at Month 4. Our primary aim is focused on cognition and will test whether NIR intervention, relative to sham, will produce pre-post improvement on tasks of recent memory (primary outcome) and executive function in older adults who are at increased risk for Alzheimer's disease. Our secondary aim is focused on neuroimaging and will test whether NIR intervention, relative to sham, will enhance brain markers of MRS-ATP (secondary outcome) and increase functional connectivity as indexed by resting state fMRI. The 3rd aim is exploratory and will evaluated how baseline demographic, genetic, neuroimaging and other factors influence individual differences in cognitive outcome for NIR intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 168
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 89 Years
Eligibility Inclusion Criteria: - Age 65-89 years, at least 8th grade education, community dwelling - Subjective report of cognitive complaints with scores >16 on the Cognitive Change Index (CCI-20) - No evidence of dementia or mild cognitive impairment based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education and sex using the NACC Uniform Data Set (UDS) norms. - No psychometric evidence of cognitive impairment based on performance on the Neuropsychological Battery from the NACC Unified Data Set, version 3. Scores on these measures cannot be lower than 1.0 SD (16th %ile) below normative values based on age, education, and gender. - Reading at > 8th grade level based on the reading subtest of the Wide Range Achievement Test- IV. - Global Clinic Dementia Rating (CDR) score must be 0 - Family history of dementia/probable Alzheimer's disease in first degree relative (parents, children, siblings) - Willingness to be randomized to Sham or Active Intervention - Can devote 12 weeks to the intervention with additional time for pre and post testing - Normal functional behavior in terms of daily activities, based on the Functional Activities Scale - Able to perform cognitive and emotion measures on a computer - In line with recommendations of SCD task force an informant must be available for two reasons: a) to provide information about the participant's complaints using the informant version of the CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire. Exclusion Criteria: - Sensory loss (vision, hearing) or motor deficits that would preclude participation in the experimental tasks or neuropsychological assessment - English as a second language - Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal - Previous major strokes or other known significant brain abnormalities or diseases affecting the brain and/or cognition (e.g.,Parkinson disease, multiple sclerosis, seizure disorder, brain surgery, moderate TBI, REM Behavior Sleep Disorder, untreated sleep apnea, etc.) - Unstable and uncontrolled medical conditions (metastatic cancer, HIV, moderate-severe kidney disease, uncontrolled diabetes, uncontrolled hypertension, severe cardiac disease, etc.). No current cancer diagnosis. - Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. - Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory) - Use of prescribed 'memory enhancing' medications such as Aricept or Namenda - Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention. - Previous participation in a cognitive training study within the last 6 months or current involvement in another study involving cognitive, physical or other intervention at the time of participation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Active NIR-PBM
See Experimental arm for description.
Sham NIR-PBM
See Sham Comparator arm for description.

Locations

Country Name City State
United States University of Florida McKnight Brain Institute Gainesville Florida
United States University of Arizona Tucson Arizona

Sponsors (3)

Lead Sponsor Collaborator
University of Florida National Institute on Aging (NIA), University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Active group ARENA scores compared to Sham group ARENA scores The primary outcome measure is a spatial navigation task (ARENA), a human analogue to the Morris WaterMaze. Participants navigate a virtual room on a computer. The task consists of 3 phases: practice, learning, and memory probe. During the learning trials, the target is invisible until the participant hovers over it. The target is located in the same location and the participant must use spatial cues to locate it. In the memory probe trial, the target is removed unbeknownst to the participant. On each learning trial, path length, time to acquire the target, and target acquisition (yes-no) are recorded. On the probe trial, path length and percent of time spent in each quadrant are recorded. The primary outcome is a composite z score, consisting of mean z scores for the following: path length(.25 weight)+time to acquire target (.25 weight)+time spent in proximal target on trial 9(.50 weight). Higher Z scores indicate better performance. Expected range of composite Z is -4 to 4. Baseline; Week 12
See also
  Status Clinical Trial Phase
Completed NCT03988829 - Strategic Training to Optimize Neurocognitive Functions in Older Adults N/A
Completed NCT03141281 - Intervention Comparative Effectiveness for Adult Cognitive Training N/A
Completed NCT02985580 - Effects of Blueberry Juice Consumption on Cognitive Function in Healthy Older People N/A
Completed NCT05980286 - Impact of Musical Improvisation Training on Cognitive Function in Older Adults N/A
Active, not recruiting NCT02977819 - Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training N/A
Completed NCT02714426 - A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults N/A
Completed NCT05462977 - Rhythmically Entrained Exercise in Community-Dwelling Older Adults N/A
Recruiting NCT05322343 - Biobank and Brain Health in Bordeaux.
Completed NCT00935493 - Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects N/A
Completed NCT00599508 - Nutritional Supplementation in Cognitive Aging N/A
Active, not recruiting NCT05455229 - Elucidating How Physical Activity and Sleep Relate to Optimal Cognitive Ageing
Terminated NCT04922710 - Physical Exercise for Augmenting Cognitive Health (PEACH) Early Phase 1
Recruiting NCT06006962 - Aging Well Through Interactions and Scientific Education - Action Plan (AgeWISE-AP) N/A
Completed NCT04904991 - Three-month Chan-Chung Qigong Improves Physical Function Performance and Quality of Life N/A
Completed NCT05672771 - The Effects of Mixed Working Memory Training on Subsequent Training Gains Among Older Adults N/A
Completed NCT03629912 - Bingocize: A Novel Mobile Application for Older Adult Health N/A
Completed NCT03677726 - Improving Sleep Continuity Through Mindfulness Training for Better Cognitive Ageing. N/A